Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
ConclusionThe efficacy of osimertinib as second-line treatment or more in octogenarian pretreated patients with EGFR T790M-mutated advanced NSCLC in a real-life setting was similar to that in randomized controlled trials.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | France Health | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Smokers | Study | Women